Anavex receives BfArM approval to conduct Phase I trial
Anavex will evaluate the safety, maximally tolerated dose, pharmacokinetics and pharmacodynamics in the Phase I trial. Anavex-2-73 represents a new class of wholly owned compounds that act through
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.